NCT06932705View on ClinicalTrials.gov

A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A

PHASE1RecruitingINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

Mixed Dyslipidemia

Interventions

DRUG

PA-111

PA-111 1Tab., Per Oral

DRUG

PA-111A

PA-111A 1Capsule., Per Oral

Trial Locations (1)

Unknown

RECRUITING

H Plus Yangji Hospital, Seoul

All Listed Sponsors

lead

Addpharma Inc.

INDUSTRY